AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 251: E431-E437, 1986;
0193-1849/86 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iguchi, A.
Right arrow Articles by Sakamoto, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iguchi, A.
Right arrow Articles by Sakamoto, N.

AJP - Endocrinology and Metabolism, Vol 251, Issue 4 431-E437, Copyright © 1986 by American Physiological Society


ARTICLES

Mechanism of central hyperglycemic effect of cholinergic agonists in fasted rats

A. Iguchi, M. Gotoh, H. Matsunaga, A. Yatomi, A. Honmura, M. Yanase and N. Sakamoto

The influence of cholinergic agonists on central nervous system (CNS) regulation of blood sugar homeostasis was studied in fasted rats. When carbachol, muscarine, bethanechol, methacholine, or neostigmine was injected into the third cerebral ventricle, it caused a dose-dependent increase in the hepatic venous plasma glucose concentration. However, in the case of 1,1-dimethylphenyl-4-piperazinium iodide (DMPP) or nicotine, the level of hepatic venous glucose did not differ from that of the saline-treated control rats. The increase in glucose level caused by neostigmine was dose-dependently suppressed by coadministration of atropine. These facts suggest that cholinergic activation of muscarinic receptors in the CNS plays a role in increasing hepatic glucose output. Injection of neostigmine (5 X 10(-8) mol), an inhibitor of cholinesterase, into the ventricle resulted in the increase of not only glucose, but also glucagon, epinephrine, and norepinephrine in the hepatic venous plasma. However, constant infusion of somatostatin through a femoral vein completely prevented the increase of glucagon after administration of neostigmine, although the increase of hepatic venous glucose and epinephrine levels were still observed. Neostigmine-induced increments in glucose did not occur in adrenalectomized rats. This suggests that the secreted epinephrine acts directly on the liver to increase hepatic glucose output.


This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
M. C. Lekas, S. J. Fisher, B. El-Bahrani, M. van Delangeryt, M. Vranic, and Z. Q. Shi
Glucose uptake during centrally induced stress is insulin independent and enhanced by adrenergic blockade
J Appl Physiol, August 1, 1999; 87(2): 722 - 731.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. Takahashi, E. Kishi, H. Ishimaru, Y. Ikarashi, and Y. Maruyama
Stimulation of rat hypothalamus by microdialysis with K+: increase of ACh release elevates plasma glucose
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1998; 275(5): R1647 - R1653.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online